Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

BOSTON, Nov. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)." Apoptone (HE3235), a novel steroid that is an analog of a dihydrotestosterone metabolic pathway member, stimulates cell death (apoptosis) in hormone-dependent prostate tumors. Presenting the data is the lead investigator of the study, R. Bruce Montgomery, M.D., Associate Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine. The poster also included supportive preclinical data.

The interim results of the Phase I/II study, which is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC), demonstrated that 47% of subjects who were radiographically evaluable for response had stable disease. With the assessment of progression every 56 days, the median time to progression was 107 days. Forty-three percent of the biochemically evaluable subjects experienced a drop in PSA during treatment, with 33% equal to or greater than a 50% decline.

Individuals experienced increases in PSA with stable disease. Plasma PSA increases are expected because the mechanism of action is believed to involve inhibition of tumor cell proliferation while the androgen receptor transcription element is engaged, independent of the androgen receptor.
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) September 30, 2014 In ... cost-effective tools to address sales, training and consumer ... has developed innovative mobile applications to turn their ... the agency’s latest customized mobile app creations, are ... . , In partnership with Toyota, StudioPMG created ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... news release is available in German . ... crystal around several quantum dots in a semiconductor layer. Quantum ... consequence of atomic processes. If a short laser pulse is ... and the quantum dot experiences a change in the electromagnetic ... down the emission of light by the dot. As soon ...
(Date:9/30/2014)... Sept. 30, 2014 Pacific Northwest Biotechnology, ... Summary Global Markets Direct,s, ,Pacific Northwest Biotechnology, ... an overview of the Pacific Northwest Biotechnology, LLC,s ... provides comprehensive information on the current therapeutic developmental ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... ARPN) announces today that it has received a ... Administration (FDA) regarding its New Drug,Application (NDA) for ... skin structure infections (cSSSI). The FDA indicated in ... iclaprim in its current form and,that additional clinical ...
... 19 /PRNewswire/ - Canada,s six genome centres demonstrated ... Annual Canadian Genomics Reception at the International Plant ... week. More than 150 researchers, funders and other ... of the informal networking event. , "This Canadian ...
... Algae is a livid green giveaway of nutrient pollution in ... tiny particles that would turn different colors if exposed to ... the blood. , Now, University of Florida engineering researchers have ... hurdle to creating such "smart dust.",The feat, which signifies a ...
Cached Biology Technology:FDA Issues Complete Response Letter for Iclaprim 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 3
(Date:9/30/2014)... People who suffer from asthma may think there,s not ... besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the scientific ... Immunology (ACAAI), asthma sufferers can learn lessons about managing ... in the Annals article improved her asthma once she ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
(Date:9/29/2014)... Plants have a symbiotic relationship with certain bacteria. ... and defend against invaders an important step ... Now, scientist have discovered that plants may package ... that sprouting plants are colonized from the beginning. ... presented their findings today at the 5th ASM ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2Plants prepackage beneficial microbes in their seeds 2
... Marine Ecosystem during 2012 were the highest recorded in ... by NOAA,s Northeast Fisheries Science Center (NEFSC). These high ... trend of above average temperature seen during the spring ... elevated temperatures occurring in the Northwest Atlantic, but not ...
... brain, the cerebral cortex undergoes a marked expansion in ... folding of the tissue in species with most expanded ... a key regulator of this crucial process. Different ... performance of specific tasks. This in turn imposes particular ...
... of Houston engineering professor has won a grant from ... the most promising therapies for patients with the disease., ... engineering, received the Stewart Rahr-MRA Young Investigator Award. The ... a therapy that has helped melanoma patients who aren,t ...
Cached Biology News:Sea surface temperatures reach highest level in 150 years 2Sea surface temperatures reach highest level in 150 years 3Developmental neurobiology: How the brain folds to fit 2University of Houston engineering professor awarded grant to study melanoma treatment 2University of Houston engineering professor awarded grant to study melanoma treatment 3
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: